Lixte Biotechnology Holdings, Inc.

NASDAQ:LIXT

Biotechnology

Healthcare
$7.21 +6.61%

+$0.46 today

Market cap
$89.11M
Beta
1.05
P/E (TTM)
-11.1
EPS (TTM)
-$0.67
52W Low $0.68High $7.78

Volume 0.61M

Average 0.12M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$5.11M

FY 2025 · Annual

Net Income

-$6.01M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development1.74M1.35M898.1K726.23K254.92K
Selling, General & Admin4.98M4.96M4.19M2.85M4.85M
Operating Expenses6.72M6.31M5.09M3.57M5.11M
Depreciation & Amortization00000
EBITDA(6.72M)(6.3M)(5.07M)(3.57M)(6M)
EBITDA Margin—————
Operating Income(6.72M)(6.31M)(5.09M)(3.57M)(5.11M)
Operating Margin—————
Interest Income62611.2K17.49K7.05K7.39K
Interest Expense7.41K8.88K16.23K16.82K9.16K
Other Income / Expenses(7.95K)(1.05K)3.21K(13.18K)(901.9K)
Income Before Tax(6.73M)(6.31M)(5.09M)(3.59M)(6.01M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(6.73M)(6.31M)(5.09M)(3.59M)(6.01M)
Net Margin—————
EPS (Basic)(5.00)(4.00)(2.66)(1.59)(1.26)
EPS (Diluted)(5.00)(4.00)(2.66)(1.59)(1.26)
Weighted Avg Shares1.35M1.58M1.91M2.25M48.41M
Weighted Avg Shares (Diluted)1.35M1.58M1.92M2.25M48.41M

LIXT Earnings Waterfall · TTM

NASDAQ:LIXT · Revenue to Net Income

Key Ratios

EPS$-1.13
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-6.9
P/S Ratio0.0

Analysis

$0 of revenue converted into -$7.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.13, tying the income statement back to per-share earnings.

Competitors

Peer companies in the same sector

Health

Recent Filings

Recent regulatory filings

FilingDescriptionDate
3Initial statement of beneficial ownershipJul 2, 2026
4Statement of changes in beneficial ownershipJul 2, 2026
4Statement of changes in beneficial ownershipJul 2, 2026
4Statement of changes in beneficial ownershipJul 2, 2026
4Statement of changes in beneficial ownershipJul 2, 2026

How much revenue does LIXT generate?

Lixte Biotechnology Holdings, Inc. (LIXT) reported $0.00 of revenue in fiscal 2025.

Is LIXT profitable?

Lixte Biotechnology Holdings, Inc. (LIXT) reported -$6.01M of net income.